ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Mueller AK, Camargo N, Kaiser K, Andorfer C, Frevert U, Matuschewski K, Kappe SH, 2005. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc Natl Acad Sci USA 102: 3022–3027.
-
2.
Mueller AK, Labaied M, Kappe SH, Matuschewski K, 2005. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433: 164–167.
-
3.
van Dijk MR, Douradinha B, Franke-Fayard B, Heussler V, van Dooren MW, van Schaijk B, van Gemert GJ, Sauerwein RW, Mota MM, Waters AP, Janse CJ, 2005. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc Natl Acad Sci USA 102: 12194–12199.
-
4.
Nussenzweig RS, Vanderberg J, Most H, Orton C, 1967. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216: 160–162.
-
5.
Belnoue E, Costa FT, Frankenberg T, Vigario AM, Voza T, Leroy N, Rodrigues MM, Landau I, Snounou G, Renia L, 2004. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol 172: 2487–2495.
-
6.
WHO, 2015. Guidelines for Treating Malaria, 3rd edition. Geneva, Switzerland: World Health Organization.
-
7.
Nganou-Makamdop K, Sauerwein RW, 2013. Liver or blood-stage arrest during malaria sporozoite immunization: the later the better? Trends Parasitol 29: 304–310.
-
8.
Butler NS, Vaughan AM, Harty JT, Kappe SH, 2012. Whole parasite vaccination approaches for prevention of malaria infection. Trends Immunol 33: 247–254.
-
9.
Vaughan AM, O'Neill MT, Tarun AS, Camargo N, Phuong TM, Aly AS, Cowman AF, Kappe SH, 2009. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell Microbiol 11: 506–520.
-
10.
Aly AS, Mikolajczak SA, Rivera HS, Camargo N, Jacobs-Lorena V, Labaied M, Coppens I, Kappe SH, 2008. Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection. Mol Microbiol 69: 152–163.
-
11.
Butler NS, Schmidt NW, Vaughan AM, Aly AS, Kappe SH, Harty JT, 2011. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 9: 451–462.
-
12.
Khan SM, Janse CJ, Kappe SH, Mikolajczak SA, 2012. Genetic engineering of attenuated malaria parasites for vaccination. Curr Opin Biotechnol 23: 908–916.
-
13.
Silvie O, Goetz K, Matuschewski K, 2008. A sporozoite asparagine-rich protein controls initiation of Plasmodium liver stage development. PLoS Pathog 4: e1000086.
-
14.
Annoura T, van Schaijk BC, Ploemen IH, Sajid M, Lin JW, Vos MW, Dinmohamed AG, Inaoka DK, Rijpma SR, van Gemert GJ, Chevalley-Maurel S, Kielbasa SM, Scheltinga F, Franke-Fayard B, Klop O, Hermsen CC, Kita K, Gego A, Franetich JF, Mazier D, Hoffman SL, Janse CJ, Sauerwein RW, Khan SM, 2014. Two Plasmodium 6-Cys family-related proteins have distinct and critical roles in liver-stage development. FASEB J 28: 2158–2170.
-
15.
van Schaijk BC, Ploemen IH, Annoura T, Vos MW, Foquet L, van Gemert GJ, Chevalley-Maurel S, van de Vegte-Bolmer M, Sajid M, Franetich JF, Lorthiois A, Leroux-Roels G, Meuleman P, Hermsen CC, Mazier D, Hoffman SL, Janse CJ, Khan SM, Sauerwein RW, 2014. A genetically attenuated malaria vaccine candidate based on P. falciparumb9/slarp gene-deficient sporozoites. Elife 3: e03582.
-
16.
Rijpma SR, van der Velden M, Gonzalez-Pons M, Annoura T, van Schaijk BC, van Gemert GJ, van den Heuvel JJ, Ramesar J, Chevalley-Maurel S, Ploemen IH, Khan SM, Franetich JF, Mazier D, de Wilt JH, Serrano AE, Russel FG, Janse CJ, Sauerwein RW, Koenderink JB, Franke-Fayard BM, 2016. Multidrug ABC transporters are essential for hepatic development of Plasmodium sporozoites. Cell Microbiol 18: 369–383.
-
17.
Janse CJ, Franke-Fayard B, Mair GR, Ramesar J, Thiel C, Engelmann S, Matuschewski K, van Gemert GJ, Sauerwein RW, Waters AP, 2006. High efficiency transfection of Plasmodium berghei facilitates novel selection procedures. Mol Biochem Parasitol 145: 60–70.
-
18.
Ploemen I, Behet M, Nganou-Makamdop K, van Gemert GJ, Bijker E, Hermsen C, Sauerwein R, 2011. Evaluation of immunity against malaria using luciferase-expressing Plasmodium berghei parasites. Malar J 10: 350.
-
19.
Franke-Fayard B, Waters AP, Janse CJ, 2006. Real-time in vivo imaging of transgenic bioluminescent blood stages of rodent malaria parasites in mice. Nat Protoc 1: 476–485.
-
20.
Jaffe RI, Lowell GH, Gordon DM, 1990. Differences in susceptibility among mouse strains to infection with Plasmodium berghei (ANKA clone) sporozoites and its relationship to protection by gamma-irradiated sporozoites. Am J Trop Med Hyg 42: 309–313.
-
21.
Prado M, Eickel N, De Niz M, Heitmann A, Agop-Nersesian C, Wacker R, Schmuckli-Maurer J, Caldelari R, Janse CJ, Khan SM, May J, Meyer CG, Heussler VT, 2015. Long-term live imaging reveals cytosolic immune responses of host hepatocytes against Plasmodium infection and parasite escape mechanisms. Autophagy 11: 1561–1579.
-
22.
Annoura T, Ploemen IH, van Schaijk BC, Sajid M, Vos MW, van Gemert GJ, Chevalley-Maurel S, Franke-Fayard BM, Hermsen CC, Gego A, Franetich JF, Mazier D, Hoffman SL, Janse CJ, Sauerwein RW, Khan SM, 2012. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. Vaccine 30: 2662–2670.
-
23.
Mikolajczak SA, Lakshmanan V, Fishbaugher M, Camargo N, Harupa A, Kaushansky A, Douglass AN, Baldwin M, Healer J, O'Neill M, Phuong T, Cowman A, Kappe SH, 2014. A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. Mol Ther 22: 1707–1715.
-
24.
Bijker EM, Borrmann S, Kappe SH, Mordmuller B, Sack BK, Khan SM, 2015. Novel approaches to whole sporozoite vaccination against malaria. Vaccine 33: 7462–7468.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 6 | 6 | 6 |
| Full Text Views | 241 | 89 | 2 |
| PDF Downloads | 64 | 24 | 2 |
Protective Efficacy Induced by Genetically Attenuated Mid-to-Late Liver-Stage Arresting Plasmodium berghei Δmrp2 Parasites
Whole parasite immunization strategies employing genetically attenuated parasites (GAP), which arrest during liver-stage development, have been applied successfully for induction of sterile malaria protection in rodents. Recently, we generated a Plasmodium berghei GAP-lacking expression of multidrug resistance-associated protein (MRP2) (PbΔmrp2) that was capable of partial schizogony in hepatocytes but showed complete growth arrest. Here, we investigated the protective efficacy after intravenous (IV) immunization of BALB/c and C57BL/6J mice with PbΔmrp2 sporozoites. Low-dose immunization using 400 PbΔmrp2 sporozoites induced 100% sterile protection in BALB/c mice after IV challenge with 10,000 wild-type sporozoites. In addition, almost full protection (90%) was obtained after three immunizations with 10,000 sporozoites in C57BL/6J mice. Parasite liver loads in nonprotected PbΔmrp2-challenged C57BL/6J mice were reduced by 86% ± 5% on average compared with naive control mice. The mid-to-late arresting PbΔmrp2 GAP was equipotent in induction of protective immunity to the early arresting PbΔb9Δslarp GAP. The combined data support a clear basis for further exploration of Plasmodium falciparum parasites lacking mrp2 as a suitable GAP vaccine candidate.
Author Notes
Authors' addresses: Maarten van der Velden, Frans G. M. Russel, and Jan B. Koenderink, Department of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands, E-mails: maarten.vandervelden@radboudumc.nl, frans.russel@radboudumc.nl, and jan.koenderink@radboudumc.nl. Sanna R. Rijpma, Geert-Jan van Gemert, Marga van de Vegte-Bolmer, Robert W. Sauerwein, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands, E-mails: sanna.rijpma@radboudumc.nl, geert-jan.vangemert@radboudumc.nl, marga.vandevegte-bolmer@radboudumc.nl, and robert.sauerwein@radboudumc.nl. Vivienne Verweij, Donders Institute for Brain, Cognition, Radboud University Medical Center, Nijmegen, The Netherlands, and Behaviour, and Department of Anatomy, Radboud University Medical Center, Nijmegen, The Netherlands, E-mail: vivienne.verweij@radboudumc.nl. Séverine Chevalley-Maurel, Blandine M. Franke-Fayard, and Chris J. Janse, Leiden Malaria Research Group, Department of Parasitology, Center of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands, E-mails: s.c.chevalley@lumc.nl, b.franke-fayard@lumc.nl, and c.j.janse@lumc.nl.